Protein Allergy Assessment
Gregory Ladics, Ph.D., DABT, ATS Research Fellow, Scientific Affairs
<b>B</b> , <b>PIONEER</b> ,



## **Food Safety in Context**

- Millions of people are sickened each year due to food borne diseases; many thousands die, even in "developed" countries
- Biotech crops are some of the most tested foods; tested to a much greater extent than foods produced by other breeding methods



## Food Safety

**Food Safety definition** 

"...a reasonable certainty that no harm will result from intended uses under the anticipated conditions of consumption."

OECD, 1993

 Traditional food bears a presumption of safety based on 'a history of safe use'

Constable et al. 2007

-While 'zero-risk' is unattainable, food should be 'safe and wholesome

- Whole GM food is assessed in comparison with traditional food to be 'as safe & nutritious as..'

## Food/Feed Safety Assessment

#### **RELATIVE SAFETY**

Historically we learned to eat "safely" through experience:

- □ Wheat must be avoided by those with celiac disease
- Legumes (beans/peas) must be cooked to inactivate lectins and trypsin inhibitors
- □ Allergic individuals must avoid specific foods


GM-Crops must be "as safe as" Non-GM GM-Crops must be "as safe as" Non-GM But, you can NOT guarantee absolute safety! SAFETY FOCUS IS ON THE NEW GENE-PROTEIN



## How do we know GM products are safe?


 There is a comprehensive safety assessment program!





## Holistic Approach





Comparison of the GM crop to a conventional equivalent with a History of Safe Use (HOSU) guides the safety assessment



## **Protein Allergy Assessment**

## Protein-specific IgE is the key mediator in Food Allergy

#### **Sensitized** Antigen IgE Mediated Symptoms **Specific B** cells 10 to 20 minutes after Make IgE allergen eating: Peanut hives (Ara h 1) (2 IgE epitopes) angioedema **IgE** asthma FcεRI diarrhea/vomiting Mast cells release atopic dermatitis histamine

anaphylaxis

& leukotrienes



# What Are The Protein Allergenicity Concerns with Ag Biotechnology?



## Categories of Potential Health Risks Relative to Protein Allergenicity (in order of risk)


1. Transfer an existing allergen or cross-reactive protein into another crop.

2. Creation of food allergens de novo (i.e., potential to become a new allergen)

3. Alteration or quantitative increase of endogenous (existing) allergens (i.e., increasing the hazard of currently allergenic foods)

### Weight-of-the-Evidence





## **Categories of Potential Health Risks**



#### <u>Risk:</u>

Transfer an existing allergen or cross-reactive protein into another crop

Alteration or quantitative increase of endogenous (existing) allergens

Analytical methods

Endpoints to reduce risk

**Bioinformatics/Immunolog** 

per CODEX (2009):

ical methods

Creation of food allergens *de novo* 

Physical properties of protein (e.g., stability in SGF; heat)



## Allows one *primary* question to be asked: Is the protein an existing allergen?

Allows one secondary question to be asked: Is the protein likely to cross-react with an existing allergen?

Bioinformatics is not intended to answer whether a protein will "<u>become</u>" an allergen



## **Search Strategy**

- Allergen Search
  - Compare amino acid sequence of query protein to database containing sequences of food, dermal and respiratory allergens.

## University of Nebraska Allergen Database

- Industry sponsored, peer-reviewed allergen database at Univ. Nebraska
  - Peer-reviewed by clinical and research allergists from around the world: Japan, Europe, and U.S.
  - Well-defined criteria; posted on database website.
  - Inclusion of protein allergens (food, dermal, respiratory) based on available data in the public literature.
  - Updated once a year (Version 13)
  - Available free to the general public
    - www.allergenonline.org



## **Allergen Search Strategy**

- Compare amino acid sequence of query protein to database containing sequences of food, dermal and respiratory allergens.
- Evaluate sequence for amino acid identity using local alignment programs, such as BLAST (or FASTA)
  - > 35% identity over an 80 or greater amino acid window

and potential (theoretical) IgE epitope matches.

- ≥ 8 contiguous identical amino acids (EFSA 2011; Ladics et al., 2011, Reg. Toxicol. Pharmacol., 60:46-53).

## **Categories of Potential Health Risks**



#### <u>Risk:</u>

Transfer an existing allergen or cross-reactive protein into another crop

Alteration or quantitative increase of endogenous (existing) allergens Endpoints to reduce risk per CODEX (2009):

Bioinformatics/Immunolog ical methods

Analytical methods

Creation of food allergens *de novo* 

Physical properties of protein (e.g., stability in SGF; heat)

## **Specific IgE Sera Screening**



- For proteins originating from an allergenic source, or having significant homology with a known allergen, specific serum screening is conducted.
- An issue of critical importance to sera screening is the availability of <u>well characterized</u>, quality human sera from a sufficient number of patients. HIPAA; patient disclosure; IRB; utilizing serum from private citizens to support a private enterprise.
- Potential false positives/equivocal results



#### <u>Risk:</u>

Transfer an existing allergen or cross-reactive protein into another crop

Alteration or quantitative increase of endogenous (existing) allergens Endpoints to reduce risk per CODEX (2009):

**Bioinformatics/Immunolog** ical methods

Analytical methods

Creation of food allergens *de novo* 

Physical properties of protein (e.g., stability in SGF; heat)



#### <u>Risk:</u>

Transfer an existing allergen or cross-reactive protein into another crop

Alteration or quantitative increase of endogenous (existing) allergens

Endpoints to reduce risk per CODEX (2009):

Bioinformatics/Immunolog ical methods

Analytical methods

Creation of food allergens *de novo* 

Physical properties of protein (e.g., stability in SGF; heat)

## **Stability to Pepsin In Vitro**

- Protein resistance to pepsin evaluated in simulated gastric fluid (pH 1.2) containing 0.3% (w/v) pepsin.
- Digestions performed for time intervals 0, 15 and 30 seconds, 1, 2, 5, 10, 15, 20, 30, and 60 minutes at 37°C.
- Samples (each protein at each time point) then analyzed by SDS polyacrylamide gel electrophoresis and/or Western blot analysis.
- A standardized protocol for evaluating the *in vitro* pepsin resistance of proteins was established (Thomas *et al.*, Regulatory Toxicology Pharmacology, 39:87-98, 2004).

Provides a loose correlation for major food allergens (stable).

This test is not meant to "mimic" real digestion

BIONEER

pH 1.2

Pepsin

Can animal models identify allergenic food proteins?

- Active research area; no consensus
- Definite need for further evaluation
  - selectivity
  - sensitivity
  - testing with a range of proteins
- None (rodent or non-rodent) validated or widely accepted

Ladics et al., (2010). Reg. Toxicol. Pharmacol., 56:212-224



### No scientific evidence that a biotech protein or a GM crop increased allergenic risk to the susceptible public

Goodman, R.E., et al., (2008). Nat. Biotechnol., 26(1):73-81.

Goodman, R.E. and Tetteh, A.O. (2011). Curr. Allergy Asthma Rep., DOI 10.1007/S11882-011-0195-6